Products derived from plants offer potential as dual-targeting agents for experimental cerebral malaria

February 21, 2018, McGill University
Products derived from plants offer potential as dual-targeting agents for experimental cerebral malaria
Credit: McGill University

Malaria, a life-threatening disease usually caused when parasites from the Plasmodium family enter the bloodstream of a person bitten by a parasite-carrying mosquito, is a severe health threat globally, with 200 to 300 million cases annually and 445,000 deaths in 2016.

With pregnant women and children most vulnerable from infection, complications including anemia and cerebral , the most severe neurological complication from malaria, are responsible for approximately 25 percent of the in some regions of Africa.

While uncomplicated clinical malaria is treatable with antimalarial drugs, treatment options for cerebral malaria are few and those that do exist are limited in their effectiveness, a problem compounded by the emergence of resistance in the .

A recent study by researchers at McGill University conducted as a collaboration between the labs of Dr. Philippe Gros, Professor in the Department of Biochemistry and Vice-Dean, Life Science, and Dr. Jerry Pelletier, Professor in the Department of Biochemistry, shows that rocaglates – a class of naturally-derived products from plants of the Aglaia species – effectively block blood-stage parasite replication in several mouse models as well as in infected human red blood cells.

Importantly, the researchers showed that these products inhibited neurological inflammation and increased survival, including in drug-resistant isolates, highlighting the strong potential of this class of compounds to be used for therapeutic treatment of complicated malaria cases in humans.

"Rocaglates as dual-targeting agents for experimental " was published in the most recent issue of PNAS.

Explore further: Methylene blue die kills in vivo malaria parasites at speed not seen before

More information: David Langlais et al. Rocaglates as dual-targeting agents for experimental cerebral malaria, Proceedings of the National Academy of Sciences (2018). DOI: 10.1073/pnas.1713000115

Related Stories

Methylene blue die kills in vivo malaria parasites at speed not seen before

February 6, 2018
Research shows that the dye methylene blue is a safe antimalarial that kills malaria parasites at an unprecedented rate. Within two days, patients are cured of the disease and no longer transmit the parasite if they are bitten ...

Experts discover ways to tackle drug resistant parasites that cause the killer disease malaria

December 11, 2017
A new analysis of all relevant previously published clinical data shows how parasites causing malaria become resistant to a commonly used treatment for malaria in travelers.

Discovery of key molecules involved in severe malaria – new target for malaria vaccine

December 4, 2017
Malaria is one of three major infectious diseases affecting approximately 300 million people every year, accounting for about 500,000 deaths, but effective vaccine development has not been successful. Among malaria parasites ...

Promising clinical trial results could give doctors a new tool against drug-resistant strains of malaria parasite

September 13, 2017
Tulane University researchers have developed a new drug that is effective against non-severe cases of malaria, according to results from an FDA-supervised clinical trial published in the latest issue of The Lancet Infectious ...

The immune system of mice is implicated in helping malaria to move from the blood to the brain

May 6, 2016
By studying malaria in mice, three A*STAR researchers have discovered how malaria parasites in the bloodstream can affect the brain, causing a life-threatening condition called cerebral malaria.

Recommended for you

Breakthrough could impact cancer, ageing and heart disease

July 20, 2018
A team of Sydney scientists has made a groundbreaking discovery in telomere biology, with implications for conditions ranging from cancer to ageing and heart disease. The research project was led by Dr. Tony Cesare, Head ...

Enzyme identified as possible novel drug target for sickle cell disease, Thalassemia

July 19, 2018
Medical researchers have identified a key signaling protein that regulates hemoglobin production in red blood cells, offering a possible target for a future innovative drug to treat sickle cell disease (SCD). Experiments ...

Supplement may ease the pain of sickle cell disease

July 19, 2018
(HealthDay)—An FDA-approved supplement reduces episodes of severe pain in people with sickle cell disease, a new clinical trial shows.

Mice given metabolite succinate found to lose weight by turning up the heat

July 19, 2018
A team of researchers with members from institutions across the U.S. and Canada has found that giving the metabolite succinate to mice fed a high-fat diet prevented obesity. In their paper published in the journal Nature, ...

Scientists uncover DNA 'shield' with crucial roles in normal cell division

July 18, 2018
Scientists have made a major discovery about how cells repair broken strands of DNA that could have huge implications for the treatment of cancer.

Researchers develop novel bioengineering technique for personalized bone grafts

July 18, 2018
Scientists from the New York Stem Cell Foundation (NYSCF) Research Institute have developed a new bone engineering technique called Segmental Additive Tissue Engineering (SATE). The technique, described in a paper published ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.